Skip to main content
Log in

Kinetics of diphenylhydantoin in uraemic patients: Consequences of decreased plasma protein binding

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Diphenylhydantoin (2 mg/kg) was infused intravenously in four uraemic patients and four healthy volunteers and its plasma concentration measured during and after the infusion. The plasma concentrations were considerably lower in the uraemic subjects and the apparent volume of distribution was higher. These observations could be explained by the lower plasma protein binding of diphenylhydantoin in the uraemics. The overall elimination rate constant β was greater (shorter half-life) in the uraemic patients. This difference could not be explained by reduced plasma protein binding, but it might be due to induction of diphenylhydantoin metabolism in the uraemic state. it is concluded that monitoring of the plasma levels of drugs in uraemic patients should be combined with determination of the extent to which the compounds are bound to plasma proteins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Odar-Cederlöf, I., Lunde, P., Sjöqvist, F.: Abnormal pharmacokinetics of phenytoin in a patient with uraemia. Lancet1970 II, 831–832

    Google Scholar 

  2. Reidenberg, M., Odar-Cederlöf, I., Bahr, von C., Borgå, O., Sjöqvist, F.: Protein binding of diphenylhydantoin and desmethylimipramin in plasma from patients with poor renal function. New Engl. J. Med.285, 264–267 (1971)

    Google Scholar 

  3. Berlin, A., Agurell, S., Borgå, O., Lund, L., Sjöqvist, F.: Micromethod for the determination of diphenylhydantoin in plasma and cerebrospinal fluid — a comparison between a gas chromatographic and spectrophotometric method. Scand. J. clin. lab. Invest.29, 281–287 (1972)

    Google Scholar 

  4. Ehrnebo, M., Agurell, S., Jalling, B., Boréus, L.-O.: Age differences in drug binding by plasma proteins: studies on human fetuses, neonates and adults. Europ. J. clin. Pharmacol.3, 189–193 (1971)

    Google Scholar 

  5. Wagner, J. G.: Pharmacokinetics. J. M. Richards Laboratory, Grosse Pointe Park, Mich. USA, 1969

    Google Scholar 

  6. Dixon, W. J., Massey, J.: Introduction to statistical analysis. New York: McGraw-Hill Book Co 1957

    Google Scholar 

  7. Gibaldi, M.: Effect of mode of administration on drug distribution in a two-compartment open system. J. Pharm. Sci.58, 327–331 (1969)

    Google Scholar 

  8. Unger, A. H., Sklaroff, H. J.: Fatalities following intravenous use of sodium diphenylhydantoin for cardiac arrhythmias. J. Amer. med. Ass.200, 159–160 (1967)

    Google Scholar 

  9. Editorial: Cardiac arrhythmias and sodium diphenylhydantoin — an appraisal. J. Amer. med. Ass.201, 142–143 (1967)

    Google Scholar 

  10. Arnold, K., Gerber, N.: The rate of decline of diphenylhydantoin in human plasma. Clin. Pharm. Ther.11, 121–134 (1970)

    Google Scholar 

  11. Gerber, N., Wagner, J. G.: Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation. Res. Commun. Chem. Pathol. Pharmacol.3, 455–466 (1972)

    Google Scholar 

  12. Benet, L. Z., Ronfeld, R. A.: Volume terms in pharmacokinetics. J. Pharm. Sci.58, 639–641, (1969)

    Google Scholar 

  13. Suzuki, T., Saitoh, Y., Nishihara, K.: Kinetics of diphenylhydantoin disposition in man. Chem. Pharm. Bull.18 (2), 405–411 (1970)

    Google Scholar 

  14. Letteri, J. M., Mellk, H., Louis, S., Kutt, H., Durante, P., Glazko, A.: Diphenylhydantoin metabolism in uremia. New Engl. J. Med.285, 648–652 (1971)

    Google Scholar 

  15. Bigger, J. T., Schmidt, D. H., Kutt, H.: Relationship between the plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effects. Circulation38, 363–374 (1968)

    Google Scholar 

  16. Lasseter, K.: Treatment of arrhythmias: basic considerations. Med. Clin. N. Amer.55, 435–444 (1971)

    Google Scholar 

  17. Helfant, R. H., Scherlag, B. J., Dameto, A. N.: The electrophysiological properties of diphenylhydantoin sodium as compared to procaineamide on the normal and digitalis-intoxicated heart. Circulation36, 108–118 (1967)

    Google Scholar 

  18. Ekelund, L.-G., Moberg, A., Olsson, A. G., OrÖ, L.: Recent myocardial infarction and the conduction system. Brit. Heart J.,34, 774–780 (1972)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Odar-Cederlöf, I., Borgå, O. Kinetics of diphenylhydantoin in uraemic patients: Consequences of decreased plasma protein binding. Eur J Clin Pharmacol 7, 31–37 (1974). https://doi.org/10.1007/BF00614387

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00614387

Key words

Navigation